Related references
Note: Only part of the references are listed.Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells
Tugba Bagci-Onder et al.
BRAIN (2015)
Pre-activated human mesenchymal stromal cells in combination with doxorubicin synergistically enhance tumor-suppressive activity in mice
Nara Yoon et al.
CYTOTHERAPY (2015)
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide
Khaled Messaoudi et al.
DRUG DISCOVERY TODAY (2015)
Targeting TRAIL in the treatment of cancer: new developments
Bora Lim et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2015)
High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells
Parvinder Hothi et al.
Oncotarget (2015)
Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin
Dae-Hee Lee et al.
ANTI-CANCER DRUGS (2014)
Getting TRAIL back on track for cancer therapy
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines
Guangxu Jin et al.
DRUG DISCOVERY TODAY (2014)
Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs
Rajapaksha Gedara Prasad Tharanga Jayasooriya et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2014)
Biochemical and Proteomic Analysis of a Potential Anticancer Agent: Palladium(II) Saccharinate Complex of Terpyridine Acting through Double Strand Break Formation
Zelal Adiguzel et al.
JOURNAL OF PROTEOME RESEARCH (2014)
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Pengfei Jiang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Sensitizing cancer cells to TRAIL-induced death by micellar delivery of mitoxantrone
Taraka Sai Pavan Grandhi et al.
NANOMEDICINE (2014)
Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo
Emilie Denicolaie et al.
ONCOTARGET (2014)
Reactive Oxygen Species Responsive Nanoprodrug to Treat Intracranial Glioblastoma
Bong-Seop Lee et al.
ACS NANO (2013)
Crosstalk between apoptosis, necrosis and autophagy
Vassiliki Nikoletopoulou et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2013)
Translating TRAIL-receptor targeting agents to the clinic
Martha W. den Hollander et al.
CANCER LETTERS (2013)
Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation
Mi Jin Yoon et al.
CARCINOGENESIS (2013)
Anticancer Effects of Niclosamide in Human Glioblastoma
Anja Wieland et al.
CLINICAL CANCER RESEARCH (2013)
Small-molecule activation of the TRAIL receptor DR5 in human cancer cells
Gelin Wang et al.
NATURE CHEMICAL BIOLOGY (2013)
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors
T. Bagci-Onder et al.
ONCOGENE (2013)
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
L. Y. Dimberg et al.
ONCOGENE (2013)
Caspase Functions in Cell Death and Disease
David R. McIlwain et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Novel Delivery Strategies for Glioblastoma
Jiangbing Zhou et al.
CANCER JOURNAL (2012)
A programmable microfluidic cell array for combinatorial drug screening
Jeongyun Kim et al.
LAB ON A CHIP (2012)
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2012)
Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines
Moo Rim Kang et al.
ONCOLOGY LETTERS (2012)
Functional Drug Screening Assay Reveals Potential Glioma Therapeutics
Christian E. Badr et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2011)
Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells
David J. Taylor et al.
BMC CANCER (2011)
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents
Wenge Wang et al.
CANCER BIOLOGY & THERAPY (2011)
Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells
D. R. Kim et al.
CANCER GENE THERAPY (2011)
Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis
Thomas Unterkircher et al.
CLINICAL CANCER RESEARCH (2011)
TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes
Liangran Guo et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway
Christian E. Badr et al.
NEURO-ONCOLOGY (2011)
HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis
J. C. Morales et al.
CANCER LETTERS (2010)
Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL
Alena Vaculova et al.
MOLECULAR CANCER (2010)
Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis
Darren Finlay et al.
PLOS ONE (2010)
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers
Nancy Lynn Booth et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Sensitization by 5-Azacytidine toward Death Receptor-Induced Hepatic Apoptosis
Timo Weiland et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
Shawn Hingtgen et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Novel therapeutic applications of cardiac glycosides
Ioannis Prassas et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
Ailsa J. Frew et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Benzethonium chloride: A novel anticancer agent identified by using a cell-based small-molecule screen
Kenneth W. Yip et al.
CLINICAL CANCER RESEARCH (2006)
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis
AD Brooks et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma
E Ciusani et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Share Paper
